COVID-19 Laboratory Codes (UB04 Billing)
<p>Blue Cross and Blue Shield of Kansas (BCBSKS) continues to monitor COVID-19 and the changes with billing new codes. The following new codes will be reimbursed as follows:</p>
<table>
<tbody>
<tr>
<td>
<p><strong>CPT Code</strong></p>
</td>
<td>
<p><strong>Nomenclature</strong></p>
</td>
<td>
<p><strong>MAP'd like:</strong></p>
</td>
</tr>
<tr>
<td>
<p>87426</p>
</td>
<td>
<p>INFECTIOUS AGENT ANTIGEN DETECTION BY IMMUNOASSAY TECHNIQUE, (EG, ENZYME IMMUNOASSAY [EIA], ENZYME-LINKED IMMUNOSORBENT ASSAY [ELISA], IMMUNOCHEMILUMINOMETRIC ASSAY [IMCA]) QUALITATIVE OR SEMIQUANTITATIVE, MULTIPLE-STEP METHOD; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (EG, SARS-COV, SARS-COV-2 [COVID-19])</p>
</td>
<td>
<p>87425</p>
</td>
</tr>
<tr>
<td>
<p>0223U</p>
</td>
<td>
<p>INFECTIOUS DISEASE (BACTERIAL OR VIRAL RESPIRATORY TRACT INFECTION), PATHOGEN-SPECIFIC NUCLEIC ACID (DNA OR RNA), 22 TARGETS INCLUDING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2), QUALITATIVE RT-PCR, NASOPHARYNGEAL SWAB, EACH PATHOGEN REPORTED AS DETECTED OR NOT DETECTED</p>
</td>
<td>
<p>0202U</p>
</td>
</tr>
<tr>
<td>
<p>0224U</p>
</td>
<td>
<p>ANTIBODY, SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]), INCLUDES TITER(S), WHEN PERFORMED</p>
</td>
<td>
<p>86769</p>
</td>
</tr>
</tbody>
</table>
<p> </p>
<p>If you have any questions regarding this newsletter, please contact your <a href="/providers/institutional/contact-us">BCBSKS Institutional Relations provider consultant</a>.</p>